Tech Company Inital Public Offerings
Aerie Pharmaceuticals IPO
Aerie Pharmaceuticals, based in Durham, debuted as a public company on 10/25/2013.
Transaction Overview
Company Name
Announced On
10/25/2013
Transaction Type
IPO
Amount
$67,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4301 Emperor Blvd. 400
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Overview
Aerie Pharmaceuticals is focused on developing products for the pharmaceutical treatment of glaucoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vicente Anido
Chief Financial Officer
Richard Rubino
Chief Medical Officer
Richard Lewis
Chief Scientific Officer
Casey Kopczynski
President
Thomas Mitro
VP - Bus. Development
Craig Skenes
VP - Finance
Christopher Staten
VP - Human Resources
Kathleen McGinley
VP - Manufacturing
Kenneth Ruettimann
VP - R & D
Eric Carlson
VP - Regulatory Affairs
Marvin Garrett
Browse more venture capital transactions:
Prev: 10/25/2013: Tiggly venture capital transaction
Next: 10/25/2013: FeedVisor venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs